NO20062860L - Sammensetning og fremgangsmate for styrking av biologisk tilgjengelighet - Google Patents

Sammensetning og fremgangsmate for styrking av biologisk tilgjengelighet

Info

Publication number
NO20062860L
NO20062860L NO20062860A NO20062860A NO20062860L NO 20062860 L NO20062860 L NO 20062860L NO 20062860 A NO20062860 A NO 20062860A NO 20062860 A NO20062860 A NO 20062860A NO 20062860 L NO20062860 L NO 20062860L
Authority
NO
Norway
Prior art keywords
composition
enhancing bioavailability
bioavailability
enhancing
compositions
Prior art date
Application number
NO20062860A
Other languages
English (en)
Norwegian (no)
Inventor
Liang-Chang Dong
Crystal Pollock-Dove
Jasmine Han
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of NO20062860L publication Critical patent/NO20062860L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20062860A 2003-11-19 2006-06-19 Sammensetning og fremgangsmate for styrking av biologisk tilgjengelighet NO20062860L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52342103P 2003-11-19 2003-11-19
US10/984,401 US20050181049A1 (en) 2003-11-19 2004-11-09 Composition and method for enhancing bioavailability
PCT/US2004/037927 WO2005051358A1 (en) 2003-11-19 2004-11-12 Composition and method for enhancing bioavailability

Publications (1)

Publication Number Publication Date
NO20062860L true NO20062860L (no) 2006-08-17

Family

ID=34636467

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062860A NO20062860L (no) 2003-11-19 2006-06-19 Sammensetning og fremgangsmate for styrking av biologisk tilgjengelighet

Country Status (13)

Country Link
US (1) US20050181049A1 (de)
EP (1) EP1684726A4 (de)
JP (1) JP2007511608A (de)
KR (1) KR20060109934A (de)
AR (1) AR048017A1 (de)
AU (1) AU2004292415A1 (de)
CA (1) CA2546618A1 (de)
IL (1) IL175647A0 (de)
MX (1) MXPA06005630A (de)
NO (1) NO20062860L (de)
PE (1) PE20050584A1 (de)
TW (1) TW200529884A (de)
WO (1) WO2005051358A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9808052D0 (en) 1998-04-17 1998-06-17 Secr Defence Implants for administering substances and methods of producing implants
PL2316456T3 (pl) 2003-04-29 2017-12-29 Orexigen Therapeutics, Inc. Kompozycje wpływające na utratę masy zawierające antagonistę opioidów i bupropion
MX2007004973A (es) * 2004-10-25 2007-06-14 Japan Tobacco Inc Formulacion solida con solubilidad y estabilidad mejoradas y metodo para producir la formulacion.
ZA200704246B (en) * 2004-10-25 2009-09-30 Japan Tobacco Inc Solid medicinal preparation improved in solubility and stability and process for producing the same
ES2669585T3 (es) 2004-10-29 2018-05-28 The Regents Of The University Of California Micropartículas porosas de silicio para la entrega de fármaco para el ojo
US20070009589A1 (en) * 2005-07-07 2007-01-11 Kandarapu Raghupathi Extended release compositions
WO2007041079A2 (en) * 2005-09-30 2007-04-12 Alza Corporation Banded controlled release nanoparticle active agent formulation dosage forms and methods
DK2135603T3 (da) 2005-11-22 2013-03-25 Orexigen Therapeutics Inc Sammensætninger og fremgangsmåder til øgning af insulinsensitivitet
ES2383330T3 (es) * 2005-11-28 2012-06-20 Orexigen Therapeutics, Inc. Formulación de liberación sostenida de zonisamida
AU2007203715B2 (en) * 2006-01-05 2012-08-02 Veloxis Pharmaceuticals A/S Disintegrating loadable tablets
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
WO2008060964A2 (en) 2006-11-09 2008-05-22 Orexigen Therapeutics, Inc. Unit dosage package and methods for administering weight loss medications
US8088786B2 (en) 2006-11-09 2012-01-03 Orexigen Therapeutics, Inc. Layered pharmaceutical formulations
DE102006054638B4 (de) * 2006-11-16 2014-12-04 Laburnum Gmbh Pharmazeutische Einzeldosisform
US8399007B2 (en) 2006-12-05 2013-03-19 Landec Corporation Method for formulating a controlled-release pharmaceutical formulation
WO2008070118A1 (en) 2006-12-05 2008-06-12 Landec Corporation Drug delivery
GB0709541D0 (en) * 2007-05-17 2007-06-27 Jagotec Ag Pharmaceutical excipient
FR2918277B1 (fr) * 2007-07-06 2012-10-05 Coretecholding Nouveau procede de production de formes pharmaceutiques seches hydrodispersibles et les compositions hydrodispersibles ainsi obtenues
KR20170084358A (ko) * 2007-07-10 2017-07-19 더 리전트 오브 더 유니버시티 오브 캘리포니아 선택된 조직에 조성물을 전달하는 물질 및 방법
US20090035370A1 (en) * 2007-08-02 2009-02-05 Drugtech Corporation Dosage form and method of use
US8114883B2 (en) 2007-12-04 2012-02-14 Landec Corporation Polymer formulations for delivery of bioactive materials
US20110144145A1 (en) 2008-05-30 2011-06-16 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
EP2135601A1 (de) * 2008-06-20 2009-12-23 Capsulution Nanoscience AG Stabilisierung amorpher Arzneimittel über schwammähnliche Trägermatrizen
CN102341096B (zh) 2009-03-04 2015-02-18 奥瑞克索股份公司 新型抗滥用制剂
CA2758607C (en) 2009-05-04 2018-05-15 Psivida Us, Inc. Porous silicon drug-eluting particles
CN102421419B (zh) 2009-05-08 2016-05-04 奥瑞克索股份公司 用于持续药物传递的包含地聚合物粘合剂的组合物
EP2440192A4 (de) * 2009-06-11 2013-08-28 Landec Corp Zusammensetzungen und verfahren zur materiallieferung
US9248123B2 (en) 2010-01-11 2016-02-02 Orexigen Therapeutics, Inc. Methods of providing weight loss therapy in patients with major depression
KR20140003405A (ko) 2010-09-07 2014-01-09 오렉쏘 에이비 경피 약물 투여 장치
JP6026424B2 (ja) 2010-11-01 2016-11-16 シヴィダ・ユーエス・インコーポレイテッドＰｓｉｖｉｄａ Ｕｓ， Ｉｎｃ． 治療薬送達のための生物浸食性ケイ素ベースのデバイス
US9394369B2 (en) 2011-01-03 2016-07-19 The Regents Of The University Of California Luminescent porous silicon nanoparticles for targeted delivery and immunization
ES2802048T3 (es) 2012-06-06 2021-01-15 Nalpropion Pharmaceuticals Llc Composición para uso en un método para el tratamiento de sobrepeso y obesidad en pacientes con alto riesgo cardiovascular
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
AU2014235051B2 (en) 2013-03-15 2019-01-17 Eyepoint Pharmaceuticals Us, Inc. Bioerodible silicon-based compositions for delivery of therapeutic agents
WO2017008059A1 (en) 2015-07-09 2017-01-12 The Regents Of The University Of California Fusogenic liposome-coated porous silicon nanoparticles
WO2019113079A1 (en) 2017-12-05 2019-06-13 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
JP2021505595A (ja) 2017-12-05 2021-02-18 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 結晶形およびその製造方法
SG11202113266YA (en) 2019-06-04 2021-12-30 Sunovion Pharmaceuticals Inc Modified release formulations and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06511481A (ja) * 1991-07-05 1994-12-22 ユニバーシティ オブ ロチェスター 気泡を取り込む超微小非凝集多孔質粒子
JP2700141B2 (ja) * 1993-09-17 1998-01-19 富士化学工業株式会社 リン酸水素カルシウム及びその製法並びにそれを用いた賦形剤
US5633011A (en) * 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
US5885616A (en) * 1997-08-18 1999-03-23 Impax Pharmaceuticals, Inc. Sustained release drug delivery system suitable for oral administration
SE512958C2 (sv) * 1998-04-30 2000-06-12 Triple Crown Ab Kolesterolsänkande komposition innehållande beta-sitosterol och/eller beta-sitostanol samt förfarande för dess framställning
JP4027535B2 (ja) * 1998-05-26 2007-12-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 脂溶性薬物を含有した粉末
US6174547B1 (en) * 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
EP1140012B1 (de) * 1998-12-17 2004-03-03 Alza Corporation Umwandlung von flüssigkeitsgefüllten gelatinkapseln in systeme mit gesteuerter wirkstoffabgabe durch mehrfache beschichtungen
US6342249B1 (en) * 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6793934B1 (en) * 1999-12-08 2004-09-21 Shire Laboratories, Inc. Solid oral dosage form
US6720003B2 (en) * 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
ES2739023T3 (es) * 2001-07-06 2020-01-28 Veloxis Pharmaceuticals As Aglomeración controlada
US20050175689A1 (en) * 2003-10-27 2005-08-11 Yamanouchi Pharmaceutical Co., Ltd. Coated fine particles containing drug for intrabuccally fast disintegrating tablet

Also Published As

Publication number Publication date
US20050181049A1 (en) 2005-08-18
MXPA06005630A (es) 2006-12-14
IL175647A0 (en) 2006-09-05
WO2005051358A1 (en) 2005-06-09
AR048017A1 (es) 2006-03-22
WO2005051358A8 (en) 2005-07-21
PE20050584A1 (es) 2005-08-15
TW200529884A (en) 2005-09-16
CA2546618A1 (en) 2005-06-09
EP1684726A4 (de) 2007-10-03
KR20060109934A (ko) 2006-10-23
EP1684726A1 (de) 2006-08-02
AU2004292415A1 (en) 2005-06-09
JP2007511608A (ja) 2007-05-10

Similar Documents

Publication Publication Date Title
NO20062860L (no) Sammensetning og fremgangsmate for styrking av biologisk tilgjengelighet
CO5611137A2 (es) Composiciones de clorhidrato de naltrexona
EA201000642A1 (ru) 2'-фтор-2'-дезокситетрагидроуридины в качестве ингибиторов цитидиндеаминазы
EA201200669A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
EA200800760A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
TNSN05254A1 (en) Derivatives of 2-acylamino-4-phenylthiazole, preparation method thereof and application of same in therapeutics
DE602004024572D1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
MY153424A (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the same
BRPI0414599A (pt) pirrol-indóis substituìdos
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
EA200601391A1 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
EA200701306A1 (ru) Лиофилизация виросом
EA200501928A1 (ru) Пирролодигидроизохинолины как ингибиторы pde10
ATE412649T1 (de) Substituierte heteroarylbenzofuransäuren
ES2311803T3 (es) Composiciones embolicas de silicie pirogena.
NO20062699L (no) Smelteblandingsdispergeringer
CY1109992T1 (el) Παραγωγα του αλφα-αμιναμιδιου χρησιμα ως αντιφλεγμονωδη μεσα
EA200700400A1 (ru) Производные n-(1h-индолил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии
NO20060535L (no) Aztreonam-L-lysin og fremgangsmater for fremstilling av dette
NO20071805L (no) Alkylidentetrahydronaftalenderivater, fremgangsmate for deres fremstilling og deres anvendelse som betennelseshemmere.
ATE363474T1 (de) Benzimidazole zur behandlung sexueller fehlfunktionen
EA200701852A1 (ru) Производные аминокислот
MX2008001541A (es) Metodos para la preparacion de inhibidores de polimerasa del vhc.
ATE443044T1 (de) Tace inhibitoren
ATE419242T1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application